Acquired hemophilia A

a review of recent data and new therapeutic options

Massimo Franchini, Stefania Vaglio, Giuseppe Marano, Carlo Mengoli, Sara Gentili, Simonetta Pupella, Giancarlo Maria Liumbruno

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.

Original languageEnglish
Pages (from-to)514-520
Number of pages7
JournalHematology
Volume22
Issue number9
DOIs
Publication statusPublished - Oct 21 2017

Fingerprint

Autoantibodies
Hemorrhage
Hemorrhagic Disorders
Coagulants
Factor VIII
Immunosuppressive Agents
Therapeutics
Physicians
Acquired Factor 8 deficiency

Keywords

  • Acquired hemophilia A
  • bleeding
  • eradication therapy
  • factor VIII

ASJC Scopus subject areas

  • Hematology

Cite this

Acquired hemophilia A : a review of recent data and new therapeutic options. / Franchini, Massimo; Vaglio, Stefania; Marano, Giuseppe; Mengoli, Carlo; Gentili, Sara; Pupella, Simonetta; Liumbruno, Giancarlo Maria.

In: Hematology, Vol. 22, No. 9, 21.10.2017, p. 514-520.

Research output: Contribution to journalArticle

Franchini, Massimo ; Vaglio, Stefania ; Marano, Giuseppe ; Mengoli, Carlo ; Gentili, Sara ; Pupella, Simonetta ; Liumbruno, Giancarlo Maria. / Acquired hemophilia A : a review of recent data and new therapeutic options. In: Hematology. 2017 ; Vol. 22, No. 9. pp. 514-520.
@article{8a28c9cd8a2e4c008b359a8781cc1947,
title = "Acquired hemophilia A: a review of recent data and new therapeutic options",
abstract = "Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.",
keywords = "Acquired hemophilia A, bleeding, eradication therapy, factor VIII",
author = "Massimo Franchini and Stefania Vaglio and Giuseppe Marano and Carlo Mengoli and Sara Gentili and Simonetta Pupella and Liumbruno, {Giancarlo Maria}",
year = "2017",
month = "10",
day = "21",
doi = "10.1080/10245332.2017.1319115",
language = "English",
volume = "22",
pages = "514--520",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Acquired hemophilia A

T2 - a review of recent data and new therapeutic options

AU - Franchini, Massimo

AU - Vaglio, Stefania

AU - Marano, Giuseppe

AU - Mengoli, Carlo

AU - Gentili, Sara

AU - Pupella, Simonetta

AU - Liumbruno, Giancarlo Maria

PY - 2017/10/21

Y1 - 2017/10/21

N2 - Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.

AB - Objectives: Acquired hemophilia A (AHA) is a rare, but potentially life-threatening, bleeding disorder caused by an autoantibody against factor VIII that interferes with its coagulant function. Methods: We performed a narrative review focusing on the diagnostic aspects of AHA and on the current treatment strategies with particular regard to new data and therapeutic developments. Results: The management of this severe hemorrhagic disorder is based on the control of bleeding with the use of bypassing agents and on the utilization of a variety of immunosuppressant agents with the goal of eliminating the autoantibody permanently. Conclusion: The optimal management of AHA should be multidisciplinary and requires a close collaboration between physicians from various specialties.

KW - Acquired hemophilia A

KW - bleeding

KW - eradication therapy

KW - factor VIII

UR - http://www.scopus.com/inward/record.url?scp=85018183523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018183523&partnerID=8YFLogxK

U2 - 10.1080/10245332.2017.1319115

DO - 10.1080/10245332.2017.1319115

M3 - Article

VL - 22

SP - 514

EP - 520

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 9

ER -